Identification of novel indole derivatives acting as inhibitors of the Keap1–Nrf2 interaction

Barbara Cosimelli,Giovanni Greco,Sonia Laneri,Ettore Novellino,Antonia Sacchi,Giorgio Amendola,Sandro Cosconati,Roberta Bortolozzi,Giampietro Viola
DOI: https://doi.org/10.1080/14756366.2019.1623209
2019-01-01
Journal of Enzyme Inhibition and Medicinal Chemistry
Abstract:<span>Nine indole derivatives (<b>9a-i</b>) were tested as potential inhibitors of the Keap1–Nrf2 interaction. This class of compounds increases the intracellular levels of the transcription factor Nrf2 and the consequent expression of enzymes encoded by genes containing the antioxidant response element (ARE). In the ARE-luciferase reporter assay only <b>9e</b>-<b>g</b> revealed to be remarkably more active than <i>t</i>-butylhydroxyquinone (<i>t</i>-BHQ), with <b>9g</b> standing out as the best performing compound. While <b>9e</b> and <b>9f</b> are weak acids, <b>9g</b> is an ampholyte prevailing as a zwitterion in neutral aqueous solutions. The ability of <b>9e-g</b> to significantly increase levels of Nrf2, NADPH:quinone oxidoreductase 1, and transketolase (TKT) gave further support to the hypothesis that these compounds act as inhibitors of the Keap1–Nrf2 interaction. Docking simulations allowed us to elucidate the nature of the putative interactions between <b>9g</b> and Keap1.<b>GRAPHICAL </b></span>
biochemistry & molecular biology,chemistry, medicinal
What problem does this paper attempt to address?